206. Chabre O. et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients // Endocr. Relat. Cancer. 2013. Vol. 20, № 4. P. 579–594.
207. Soon P.S.H. et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer // Clin. Cancer Res. 2009. Vol. 15, № 24. P. 7684–7692.
208. Barreau O. et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas // J. Clin. Endocrinol. Metab. 2013. Vol. 98, № 1. P. 174–184.
209. Mohan D.R. et al. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma // Clin Cancer Res. 2019. Vol. 25 №11. P. 3276-3288.
210. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, Berruti A. Management of adrenal cancer: a 2013 update. Endocrinol Invest. 2014;37(3):207-17. doi: 10.1007/s40618-013-0049/
211. Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical Carcinoma with Hypercortisolism. Endocrinol Metab Clin North Am. 2018 Jun;47(2):395-407. doi: 10.1016/j.ecl.2018.02.003. Epub 2018 Apr 9. PMID: 29754640.
212. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, Else T. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013 Aug 20;31(24):3012-8. doi: 10.1200/JCO.2012.48.0988. Epub 2013 Jul 22. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612. PMID: 23752102; PMCID: PMC3739861.
213. suboi I, Kardoust Parizi M, Matsukawa A, Mancon S, Miszczyk M, Schulz RJ, Fazekas T, Cadenar A, Laukhtina E, Kawada T, Katayama S, Iwata T, Bekku K, Wada K, Remzi M, Karakiewicz PI, Araki M, Shariat SF. The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis. Urol Oncol. 2024 Oct 7:S1078-1439(24)00654-9. doi: 10.1016/j.urolonc.2024.09.014. Epub ahead of print. PMID: 39379210.
214. Горбунова В.А., Бельцевич Д.Г., Бохян В.Ю. и соавт. Рак коры надпочечника. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):445–451.
215. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Nov;31(11):1476-1490. doi: 10.1016/j.annonc.2020.08.2099. Epub 2020 Aug 27. Erratum in: Ann Oncol. 2023 Jul;34(7):631. doi: 10.1016/j.annonc.2022.12.006. PMID: 32861807.
216. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2025. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2025.
217. Zhulikov YA, et al. Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study. Ann Oncol. 2024;35(Suppl): S537.
218. Laganà M, Grisanti S, Ambrosini R, Cosentini D, Abate A, Zamparini M, Ferrari VD, Gianoncelli A, Turla A, Canu L, Terzolo M, Tiberio GAM, Sigala S, Berruti A. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ESMO Open. 2022 Apr;7(2):100422. doi: 10.1016/j.esmoop.2022.100422. Epub 2022 Mar 7. PMID: 35272132; PMCID: PMC9058897.
219. Oldenburger E, Brown S., Willmann J., et al ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol. 2022 Aug; 173:240-253. doi: 10.1016/j.radonc.2022.06.002.
220. Фогт С.Н., Калугина В.В., Ворохобина Н.В., Кузнецова А.В., Серебрякова И.П. Текущий статус лекарственной терапии аденокортикального рака. Медицинский вестник Юга России. 2022;13(2):154-161. https://doi.org/10.21886/2219-8075-2022-13-2-154-161.
221. Cifu D. X., Lew H. L. Braddom s Rehabilitation Care: A Clinical Handbook E-Book. – Elsevier Health Sciences, 2017.
222. Van den Berg J. P. et al. Guideline" Cancer rehabilitation" //Nederlands tijdschrift voor geneeskunde. – 2011. – Т. 155. – №. 51. – С. A4104.
223. Fu J. B., Morishita S. The future of rehabilitation in oncology. – 2017.
224. Poirier J, Godemel S, Mourot A, Grunenwald S, Olney HJ, Le XK, Lacroix A, Caron P, Bourdeau I. Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2336-2342. doi: 10.1210/clinem/dgad115. PMID: 36856782.
225. Magkou D, Do Cao C, Bouvattier C, Douillard C, de Marcellus C, Cazabat L, Gérard M, Raffin-Sanson ML, Young J. Foetal exposure to mitotane/Op'DDD: Post-natal study of four children. Clin Endocrinol (Oxf). 2018 Dec;89(6):805-812. doi: 10.1111/cen.13854. Epub 2018 Oct 16. PMID: 30222204.
226. Жуликов Я.А. Лекарственная терапия и роль повторных хирургических вмешательств в лечении местнораспространенного и метастатического адренокортикального рака: дис. ... канд. мед. наук: 3.1.6 – Онкология, лучевая терапия / ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России. – М., 2025.
227. Bianchini M, Puliani G, Chiefari A, Mormando M, Lauretta R, Appetecchia M. Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review. Cancers (Basel). 2021 Oct 5;13(19):5001. doi: 10.3390/cancers13195001. PMID: 34638485; PMCID: PMC8508479.
228. Ma S, Wu L, Ye L, Habra MA, Balderrama-Brondani V, Wang W. Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma. Endocrine. 2025 Jan 25. doi: 10.1007/s12020-025-04163-5. Epub ahead of print. PMID: 39862362.
229. Ribeiro R, Figueiredo B. Childhood adrenocortical tumours. Eur J Cancer. 2004;40(8):1117–1126. doi: 10.1016/j.ejca.2004.01.031